Invizius aims to transform care on dialysis, and other extra-corporeal treatments

Extra-corporeal treatments like dialysis, cardiopulmonary bypass, and ECMO involve the circulation of the patient's blood supply through a machine. The patient's immune system treats the machine as a large, unwanted foreign body; the resulting inflammatory response contributes to a range of serious complications that drive morbidity and mortality and reduce quality of life.

Inflammation drives cardiovascular disease (CVD) which remains the leading cause of death for dialysis patients. Today, almost half of all dialysis patients die from cardiovascular complications, and life expectancy on dialysis is just one-third of normal.

Inflammation drives up the risk of respiratory, haematological and neurological complications in patients on cardiopulmonary bypass and ECMO.

With its proprietary H-Guard® biotechnology, Invizius is addressing the side effects of dialysis and other extra-corporeal treatments. 

The H-Guard® Priming Solution is under development and not available for clinical use.